Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome.

MYO/DCI ratio Polycystic ovary syndrome inositol

Journal

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
ISSN: 1473-0766
Titre abrégé: Gynecol Endocrinol
Pays: England
ID NLM: 8807913

Informations de publication

Date de publication:
Dec 2024
Historique:
medline: 19 1 2024
pubmed: 19 1 2024
entrez: 19 1 2024
Statut: ppublish

Résumé

In this article, we present a narrative review on the use of inositol in the treatment of polycystic ovary syndrome (PCOS). Of the different inositols that exist, only myo-inositol (MYO) and D-chiro inositol (DCI) have been studied in the treatment of PCOS. The results of the studies show that there is insufficient or controversial evidence to recommend the use of DCI alone, while MYO alone shows positive results and, above all, the MYO/DCI combination is effective when used at a ratio of at least 40:1, but there is enough rationale to further study ratios such as 66:1 to 100:1 as other possible effective combinations.

Identifiants

pubmed: 38239032
doi: 10.1080/09513590.2023.2301554
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2301554

Auteurs

Iñaki Lete (I)

Obstetrics and Gynaecology Clinical Management Unit, Araba University Hospital, Vitoria, Spain.

Ainara Martínez (A)

Obstetrics and Gynaecology Clinical Management Unit, Araba University Hospital, Vitoria, Spain.

Irene Lasaga (I)

Obstetrics and Gynaecology Clinical Management Unit, Araba University Hospital, Vitoria, Spain.

Eva Centurión (E)

Obstetrics and Gynaecology Clinical Management Unit, Araba University Hospital, Vitoria, Spain.

Amaia Vesga (A)

Obstetrics and Gynaecology Clinical Management Unit, Araba University Hospital, Vitoria, Spain.

Classifications MeSH